The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Ulrika Ericson

Ulrika Ericson

Associate professor

Ulrika Ericson

Flavonoid and lignan intake and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort

Author

  • Esther Molina-Montes
  • María José Sánchez
  • Raul Zamora-Ros
  • H. Bas Bueno-de-Mesquita
  • Petra A. Wark
  • Mireia Obon-Santacana
  • Tilman Kühn
  • Verena Katzke
  • Ruth C. Travis
  • Weimin Ye
  • Malin Sund
  • Alessio Naccarati
  • Amalia Mattiello
  • Vittorio Krogh
  • Caterina Martorana
  • Giovanna Masala
  • Pilar Amiano
  • José María Huerta
  • Aurelio Barricarte
  • José Ramón Quirós
  • Elisabete Weiderpass
  • Lene Angell Åsli
  • Guri Skeie
  • Ulrika Ericson
  • Emily Sonestedt
  • Petra H. Peeters
  • Isabelle Romieu
  • Augustin Scalbert
  • Kim Overvad
  • Matthias Clemens
  • Heiner Boeing
  • Antonia Trichopoulou
  • Eleni Peppa
  • Pavlos Vidalis
  • Kay Tee Khaw
  • Nick Wareham
  • Anja Olsen
  • Anne Tjønneland
  • Marie Christine Boutroun-Rualt
  • Françoise Clavel-Chapelon
  • Amanda J. Cross
  • Yunxia Lu
  • Elio Riboli
  • Eric J. Duell

Summary, in English

Despite the potential cancer preventive effects of flavonoids and lignans, their ability to reduce pancreatic cancer risk has not been demonstrated in epidemiological studies. Our aim was to examine the association between dietary intakes of flavonoids and lignans and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 865 exocrine pancreatic cancer cases occurred after 11.3 years of follow-up of 477,309 cohort members. Dietary flavonoid and lignan intake was estimated through validated dietary questionnaires and the US Department of Agriculture (USDA) and Phenol Explorer databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were calculated using age, sex and center-stratified Cox proportional hazards models, adjusted for energy intake, body mass index (BMI), smoking, alcohol and diabetes status. Our results showed that neither overall dietary intake of flavonoids nor of lignans were associated with pancreatic cancer risk (multivariable-adjusted HR for a doubling of intake = 1.03, 95% CI: 0.95–1.11 and 1.02; 95% CI: 0.89–1.17, respectively). Statistically significant associations were also not observed by flavonoid subclasses. An inverse association between intake of flavanones and pancreatic cancer risk was apparent, without reaching statistical significance, in microscopically confirmed cases (HR for a doubling of intake = 0.96, 95% CI: 0.91–1.00). In conclusion, we did not observe an association between intake of flavonoids, flavonoid subclasses or lignans and pancreatic cancer risk in the EPIC cohort.

Department/s

  • Department of Clinical Sciences, Malmö
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2016-10-01

Language

English

Pages

1480-1492

Publication/Series

International Journal of Cancer

Volume

139

Issue

7

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Cancer and Oncology
  • Public Health, Global Health, Social Medicine and Epidemiology

Keywords

  • cohort
  • diet
  • flavonoids
  • lignans
  • pancreatic cancer

Status

Published

ISBN/ISSN/Other

  • ISSN: 0020-7136